SUNPHARMA.BO - Sun Pharmaceutical Industries Limited

BSE - BSE Real Time Price. Currency in INR
401.40
0.00 (0.00%)
At close: 3:59PM IST
Stock chart is not supported by your current browser
Previous Close401.40
Open401.60
Bid0.00 x 0
Ask401.40 x 0
Day's Range397.80 - 406.40
52 Week Range350.40 - 616.50
Volume247,486
Avg. Volume362,396
Market Cap963.577B
Beta (3Y Monthly)0.62
PE Ratio (TTM)32.18
EPS (TTM)12.47
Earnings DateN/A
Forward Dividend & Yield2.75 (0.69%)
Ex-Dividend Date2019-08-20
1y Target EstN/A
  • Business Wire

    Sun Pharma Launches Drizalma Sprinkle in the U.S.

    MUMBAI, India & PRINCETON, N.J.-- -- First and only FDA-approved sprinkle formulation of delayed-release duloxetine capsules Only formulation of duloxetine that can be swallowed whole, sprinkled on applesauce or administered via nasogastric tube Third product in company portfolio designed for the 30-35% of long-term care residents who have difficulty swallowing Sun Pharmaceutical Industries Ltd. today ...

  • Business Wire

    Sun Pharma Launches CEQUA for the Treatment of Dry Eye Disease in the U.S.

    CEQUA™ 0.09% for topical ophthalmic use is the first and only approved cyclosporine treatment delivered with NCELL™ technology

  • ILUMYA™ (tildrakizumab-asmn) 3-Year Data Demonstrates Sustained Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis
    PR Newswire

    ILUMYA™ (tildrakizumab-asmn) 3-Year Data Demonstrates Sustained Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis

    -- Wide-Range of ILUMYA™ Data Shared at American Academy of Dermatology 2019 Annual Meeting Provides New Insights on Long-Term Use -- Multiple One-Year Data Analyses Show Impact of ILUMYA™ Across Different ...

  • Associated Press

    Suit: Missouri professor stole and sold student's research

    KANSAS CITY, Mo. (AP) — The University of Missouri system is suing a pharmacy professor at its Kansas City campus over allegations he stole and sold a student's research, claiming that the school is the rightful owner of the work it believes could be used to make a billion-dollar drug.

  • Reuters

    Sun Pharma third-quarter profit jumps four-fold on strong U.S. show

    Net profit came in at 12.42 billion rupees ($175.45 million) versus 3.22 billion rupees profit last year, the company said, which was above an average estimate for a profit of 9.86 billion rupees from 16 analysts, Refinitiv Eikon data shows.

  • Sun Pharma takes steps to ease governance concerns; shares rally
    Reuters

    Sun Pharma takes steps to ease governance concerns; shares rally

    The whistleblower had alleged that Sun Pharma's distributor Aditya Medisales Ltd had transactions worth more than 58 billion rupees ($814 million) with Suraksha Realty, controlled by the executive director, Sudhir Valia, a report by Moneylife magazine said. Sun Pharma said it had not received the complaint and was not privy to contents of the document. Sun Pharma said on Tuesday it replaced Aditya Medisales with its wholly owned unit as the new distributor for its domestic formulations business.

  • Reuters

    Morning News Call - India, January 21

    INDIA TOP NEWS • India sacks PNB executives for lapses in $2 billion fraud in first firings -sources India has sacked two executives of state-run Punjab National Bank for allegedly failing to prevent a $2 billion fraud, two sources said on Sunday, nearly a year after the country's biggest bank scam came to light and also dragged the government into the controversy. • SBI says lenders awaiting SEBI decision on Etihad offer for Jet Airways - paper The State Bank of India (SBI)-led consortium of lenders is waiting for India’s capital markets regulator to decide on a bailout offer by Etihad Airways for the financially stressed Jet Airways, SBI Chairman Rajnish Kumar said, the Business Standard reported on Saturday.

  • Reuters

    Sun Pharma asks SEBI to examine media report

    (Reuters) - Sun Pharmaceutical Industries Ltd on Friday asked India's capital markets regulator to look into a media report about an alleged complaint by a whistleblower that led to a sell-off in the company's ...

  • Reuters

    India's Sun Pharma asks regulator to examine media report

    Sun Pharmaceutical Industries Ltd on Friday asked India's capital markets regulator to look into a media report about an alleged complaint by a whistleblower that led to a sell-off in the company's shares. ...

  • Reuters

    Nifty, Sensex end marginally higher on Reliance Industries boost

    (Reuters) - Indian shares finished a touch higher on Friday, as earnings-driven gains in oil-to-retail conglomerate Reliance Industries Ltd helped offset sharp losses in Sun Pharmaceutical Industries Ltd. ...

  • India's Sun Pharma tumbles on reports of fresh whistleblower complaint
    Reuters

    India's Sun Pharma tumbles on reports of fresh whistleblower complaint

    The complaint, sent to capital market regulator Securities and Exchange Board of India (SEBI), is the second in over a month and comes as Sun Pharma already battles a product recall and regulatory investigation over reported insider trading. The whistleblower alleged in a 172-page complaint that Sun Pharma's distributor Aditya Medisales had transactions worth more than 58 billion rupees ($815 million) with Suraksha Realty, controlled by Sun's co-promoter Sudhir Valia, a report by Moneylife magazine said. Sun Pharma's payment to Aditya Medisales was transferred to the promoter and group companies between 2014 and 2017, Moneylife founder Debashis Basu told CNBC-TV18 in an interview.

  • Reuters

    Sun Pharma tumbles on reports of fresh whistleblower complaint

    The complaint, sent to capital market regulator Securities and Exchange Board of India (SEBI), is the second in over a month and comes as Sun Pharma already battles a product recall and regulatory investigation over reported insider trading. The whistleblower alleged in a 172-page complaint that Sun Pharma's distributor Aditya Medisales had transactions worth more than 58 billion rupees ($815 million) with Suraksha Realty, controlled by Sun's co-promoter Sudhir Valia, a report by Moneylife magazine said. Sun Pharma's payment to Aditya Medisales was transferred to the promoter and group companies between 2014 and 2017, Moneylife founder Debashis Basu told CNBC-TV18 in an interview.

  • Reuters

    Morning News Call - India, December 4

    To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_12042018.pdf If you would like to receive this newsletter via email, please register ...

  • Reuters

    Sun Pharma tumbles after report of probe

    Markets regulator Securities and Exchange Board of India (SEBI) is likely to reopen an insider trading case against Sun, a report by the PTI carried https://economictimes.indiatimes.com/markets/stocks/news/sebi-may-reopen-insider-trading-case-against-sun-pharma/articleshow/66887801.cms in Indian daily Economic Times said. The SEBI will also probe alleged lapses by some of Sun's promoters in raising funds overseas, the report added. A whistleblower approached the SEBI with a document alleging various irregularities by the Mumbai-headquartered company, its promoter Dilip Shanghvi and others, the report said.

  • Sun Pharma swings to surprise quarterly loss
    Reuters

    Sun Pharma swings to surprise quarterly loss

    India's largest drugmaker by market capitalisation made a provision of 12.14 billion rupee ($167 million) for estimated settlements with remaining plaintiffs in U.S. antitrust litigation related to its sleep disorder drug Modafinil, leaving it with a 2.19 billion rupee loss in the three months to Sept. 30, the company said on Tuesday.

  • Reuters

    Indian drugmaker Sun Pharma swings to surprise quarterly loss

    Sun Pharmaceutical Industries was sent to an unexpected second-quarter loss by a one-off charge for an antitrust litigation settlement. India's largest drugmaker by market capitalisation made a provision of 12.14 billion rupee ($167 million) for estimated settlements with remaining plaintiffs in U.S. antitrust litigation related to its sleep disorder drug Modafinil, leaving it with a 2.19 billion rupee loss in the three months to Sept. 30, the company said https://www.bseindia.com/xml-data/corpfiling/AttachLive/45c41034-691b-4a84-84b4-a2e0e0f6d530.pdf on Tuesday.

  • Reuters

    India's Sun Pharma posts surprise quarterly loss on one-time charge

    Sun Pharmaceutical Industries Ltd , India's largest drugmaker by market capitalisation, posted a surprise quarterly loss on Tuesday, hurt by a one-time charge due to a legal settlement. Net loss came in ...

  • Sun Pharma Announces the Availability of ILUMYA™ (tildrakizumab-asmn) in the United States for the Treatment of Moderate-to-Severe Plaque Psoriasis
    PR Newswire

    Sun Pharma Announces the Availability of ILUMYA™ (tildrakizumab-asmn) in the United States for the Treatment of Moderate-to-Severe Plaque Psoriasis

    New Insights on the Cost-Effectiveness of ILUMYA™ Presented Today at the Academy of Managed Care Pharmacy Nexus 2018 Meeting MUMBAI, India and PRINCETON, N.J. , Oct. 23, 2018 /PRNewswire/ -- Sun Pharmaceutical ...